ClinicalTrials.gg
CompletedNCT06942923Updated Oct 7, 2025

A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity

A Phase 1 interventional study of AZD4144 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Atherosclerosis by AstraZeneca — 1 open to participants now, 2 under way, 2 of them phase 3. Atherosclerosis · AstraZeneca.

Enrollment
13th of 14
28 · median 84
Started
2025
with 2 others
Phase 1
7 of 21
none open now
Registered
19th of 21
by date

Among the 21 studies in Atherosclerosis by AstraZeneca, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 1, and was the 19th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

1 of the 21 studies in Atherosclerosis by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Atherosclerosis by AstraZeneca, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.

Read the detailed description

This is placebo-controlled, parallel group and single centre study in healthy male and female participants with obesity and no known Atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or Type 2 Diabetes Mellitus.

Participants will be randomized in the ratio of 1:1 to receive either AZD4144 or placebo.

This study will comprise of:

  • A screening period of 28 days.
  • The treatment duration will be up to 28 days.
  • The visit frequency will be weekly up to a Follow-up Visit, followed by a Final Follow-up Visit 28 days after the final dose of AZD4144.
03

Conditions studied

  • Healthy Participants

Keywords

  • Cardiorenal disease
  • Atherosclerotic cardiovascular disease
  • Chronic kidney disease
  • Type 2 Diabetes Mellitus
  • Atherosclerosis
  • Obesity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Serum hsCRP > 2 milligrams per liter (mg/L).
  • All females must have a negative pregnancy test at the Screening Visit and at the randomization visit (Visit 2).
  • Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective to avoid pregnancy from the time of first administration of study intervention until 3 months after the Final Follow-up Visit.
  • Have a (BMI) greater than or equal to (≥) 30 and less than or equal to (≤) 45 kilograms per meter\^2 (kg/m\^2).

Key Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History of Myocardial infarction (MI), coronary revascularisation, stroke, revascularisation for peripheral arterial disease, or other pre-existing Cardiovascular (CV) diseases.
  • History of Diabetes (Type 1 and Type 2) or (HbA1c) ≥6.5%.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any skin disorder, history of, or ongoing clinically significant allergy/.
  • Clinically significant serious active and chronic infections within 60 days prior to randomization.
  • Known history of primary immunodeficiency (congenital or acquired) or an underlying condition that predisposes to infection.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    AZD4144

    Participants will receive a single oral dose of AZD4144 under fasted conditions once daily for 28 days.

    Drug: AZD4144

  • Placebo comparator
    Placebo

    Participants will receive a single oral dose of matching placebo to AZD4144 under fasted conditions once daily for 28 days.

    Drug: Placebo

Interventions

  • AZD4144 will be administered orally as per arms they have been assigned.

  • DrugPlacebo

    Placebo will be administered orally as per arms they have been assigned.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    The safety and tolerability of AZD4144 compared with placebo will be assessed.

    Time frame: From Screening (Day -28 to Day -2) to final follow-up (Day 56)

  2. Relative change from baseline in systemic interleukin-6 (IL-6) levels

    The effect of AZD4144 on circulating inflammatory biomarker IL-6 compared with placebo will be assessed.

    Time frame: From baseline to 4 weeks

Secondary outcomes

  1. Relative change from baseline in systemic IL-18 levels

    The effect of AZD4144 compared with placebo on circulating biomarker IL-18 will be assessed.

    Time frame: From baseline to 4 weeks

  2. Relative change from baseline in high-sensitivity C-reactive protein (hsCRP) levels

    The effect of AZD4144 compared with placebo on circulating biomarker hsCRP will be assessed.

    Time frame: From baseline to 4 weeks

  3. Observed lowest concentration before the next dose is administered (Ctrough) of AZD4144

    The pharmacokinetics (PK) of AZD4144 in participants with obesity will be assessed.

    Time frame: From Day 1 to Day 28

  4. Maximum observed drug concentration (Cmax) of AZD4144

    The PK of AZD4144 in participants with obesity will be assessed.

    Time frame: From Day 1 to Day 28

  5. Time to reach maximum observed concentration (tmax) of AZD4144

    The PK of AZD4144 in participants with obesity will be assessed.

    Time frame: From Day 1 to Day 28

07

Study locations

1 site
  • Research Site
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST /Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Sep 2025, 5 months.

Of 32 phase 1 interventional studies under Atherosclerosis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 41. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 24, 2025
StartActual
Apr 22, 2025
Primary completionActual
Sep 29, 2025
CompletionActual
Sep 29, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942923
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Apr 22, 2025
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025
Last update
Oct 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berzanoflast

Start the discussion